
|Videos|May 12, 2022
Side Effects of IO/TKI Treatment Regimens for Renal Cell Carcinoma
Author(s)Thomas E. Hutson, DO, PharmD
Thought leaders explain how they dose IO/TKI treatment regimens to better manage side effects in patients with renal cell carcinoma.
Advertisement
Episodes in this series

Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
Advertisement
Advertisement
Advertisement
Trending on CancerNetwork
1
All-Oral Revumenib Regimen May Show Advantage in Newly Diagnosed AML
2
Talquetamab Combo Yields Responses in Multiple Myeloma With True EMD
3
Linvoseltamab Yields High Response in Newly Diagnosed Multiple Myeloma
4
MARIPOSA Final OS Results in Asia Population Yield Meaningful Improvement in EGFR NSCLC
5




























































































